Peer Review reports
From: Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
| Original Submission | ||
|---|---|---|
| 4 Apr 2022 | Submitted | Original manuscript |
| 18 Jul 2022 | Reviewed | Reviewer Report - Jr-wei Wu |
| 19 Jul 2022 | Reviewed | Reviewer Report |
| 2 Sep 2022 | Author responded | Author comments - Soo-Jin Cho |
| 15 Sep 2022 | Reviewed | Reviewer Report |
| 19 Sep 2022 | Reviewed | Reviewer Report - Jr-wei Wu |
| 22 Sep 2022 | Author responded | Author comments - Soo-Jin Cho |
| Resubmission - Version 2 | ||
| 2 Sep 2022 | Submitted | Manuscript version 2 |
| 28 Sep 2022 | Reviewed | Reviewer Report |
| 1 Oct 2022 | Reviewed | Reviewer Report - Jr-wei Wu |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| Publishing | ||
| 3 Oct 2022 | Editorially accepted | |
| 8 Oct 2022 | Article published | 10.1186/s10194-022-01505-w |
You can find further information about peer review here.